Adding patient-reported health updates to cancer team treatment planning meetings
Tests sharing patients' own health reports in tumor board meetings for several cancers.
Plain-language title generated from the registry record
Registry title: INtegrating Systematic PatIent-Reported Evaluations in Multi-Disciplinary Tumor Boards: The INSPIRE Study
Key facts
- Where
- Birmingham, Los Angeles, and Oklahoma City, United StatesSee the 3 sites
Where in United States
- University of Alabama at BirminghamBirmingham, United StatesTaking people
- University of California Los Angeles (UCLA).Los Angeles, United StatesNot yet recruiting
- University of Oklahoma (OU) Health CampusOklahoma City, United StatesNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Alabama at Birmingham
- Trial code
- NCT07671937
- Record updated
- 5 November 2026
- Original description
The purpose of the study is to characterize baseline multidisciplinary tumor board (MDTB) context and variability, evaluate the relationship between baseline fitness of patients with cancer and initial treatment recommendations, and assess the impact of the INSPIRE intervention, which involves including electronic patient reported outcomes (ePROs) within MDTB on MDTB discussion content, provider burden, treatment recommended and received, healthcare utilization, and patient-reported outcomes.Read full original descriptionShow less
INtegrating Systematic PatIent-Reported Evaluations in Multi-Disciplinary Tumor Boards: The INSPIRE Study
The purpose of the study is to characterize baseline multidisciplinary tumor board (MDTB) context and variability, evaluate the relationship between baseline fitness of patients with cancer and initial treatment recommendations, and assess the impact of the INSPIRE intervention, which involves including electronic patient reported outcomes (ePROs) within MDTB on MDTB discussion content, provider burden, treatment recommended and received, healthcare utilization, and patient-reported outcomes.
Inclusion: Inclusions Criteria- Patients:; aged 18 years or older; with suspected or confirmed diagnosis of pancreatic, breast, and gynecologic cancer (all stages) within 8 weeks of diagnosis. This may include diagnosis of a new recurrence. Patients may have had some treatment prior to being seen at a participating institution as long as they are within the 8-week timeframe. Patients may be diagnosed at a participating institution or outside. If there is diagnostic uncertainty and/or patient has not received treatment they will be allowed to participate if they are beyond the 8 weeks of diagnosis; intention to be treated at a participating institution; with verbal fluency in English or Spanish; and; scheduled to be discussed at MDTB; Inclusion criteria - Clinicians:; All clinical team members participating in the pancreatic, breast, or gynecologic MDTB at a participating site will be included and have pre-emptively agreed to participation.
Exclusion: Exclusion criteria - Patients:; Individuals with plans to receive cancer treatment outside the participating institution and inability to speak English or Spanish; Exclusion criteria - Clinician:; Clinicians will retain the opportunity to opt-out of participation, in which case their portions of the discussion will not be included in the analysis; however, this is not anticipated based on pilot data.
Inclusion/Exclusion Criteria: We will include two populations: (1) patients and (2) clinical team members involved in the MDTB.